Treatment of advanced lung adenocarcinoma with EGFR L833V/H835L compound mutations using furmonertinib: two case reports and literature review

BackgroundLung cancer remains the leading cause of cancer-related mortality worldwide. With advancements in molecularly targeted therapies, Epidermal growth factor receptor (EGFR) mutations have emerged as critical therapeutic targets in advanced lung adenocarcinoma. However, the EGFR p.L833V/p.H835...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Shize Wang, Guoliang Shi, Qingyi Liu, Guangjie Liu, Yanjie Liu, Yaqing Han, Maogang Gao, Kaihong Han, Shaonan Xie
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2025-09-01
Serija:	Frontiers in Medicine
Teme:	lung adenocarcinoma EGFR mutation p.L833V/p.H835L compound mutation furmonertinib case report
Online dostop:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1658583/full
Oznake:	Označite Brez oznak, prvi označite!